Bevaas Use In Pregnancy & Lactation

Pregnancy: Angiogenesis has been shown to be critically important to fetal development. The inhibition of angiogenesis following administration of Bevacizumab could result in an adverse outcome of pregnancy.
There are no adequate and well-controlled studies in pregnant women. IgGs are known to cross the placental barrier, and Bevacizumab may inhibit angiogenesis in fetus. In the post marketing setting, cases of foetal abnormalities in women treated with Bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed.
Therefore, Bevacizumab should not be used during pregnancy. In women with childbearing potential, appropriate contraceptive measures should be used during Bevacizumab therapy. Based on pharmacokinetic considerations, contraceptive measures should be used for at least 6 months following the last dose of Bevacizumab.
Fertility: Repeat dose safety studies in animals have shown that Bevacizumab may have an adverse effect on female fertility. A substudy with 295 premenopausal women has shown a higher incidence of new cases of ovarian failure in the Bevacizumab innovator group compared to the control group. After discontinuation of Bevacizumab treatment, ovarian function recovered in the majority of patients. Long term effects of the treatment with Bevacizumab on fertility are unknown.
Labour and Delivery: No information available.
Lactation: It is not known whether Bevacizumab is excreted in human milk. As maternal IgG is excreted in milk and Bevacizumab could harm infant growth and development, women should be advised to discontinue nursing during Bevacizumab therapy and not to breast feed for at least 6 months following the last dose of Bevacizumab.